A detailed history of Abel Hall, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Abel Hall, LLC holds 6,191 shares of GILD stock, worth $565,547. This represents 0.34% of its overall portfolio holdings.

Number of Shares
6,191
Previous 6,390 3.11%
Holding current value
$565,547
Previous $438 Million 18.39%
% of portfolio
0.34%
Previous 0.31%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

SELL
$66.59 - $83.99 $13,251 - $16,714
-199 Reduced 3.11%
6,191 $519 Million
Q2 2024

Jul 25, 2024

SELL
$63.15 - $72.88 $24,754 - $28,568
-392 Reduced 5.78%
6,390 $438 Million
Q1 2024

May 08, 2024

BUY
$71.58 - $87.29 $138,865 - $169,342
1,940 Added 40.07%
6,782 $497 Million
Q4 2023

Feb 28, 2024

BUY
$73.27 - $83.09 $354,773 - $402,321
4,842 New
4,842 $392 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Abel Hall, LLC Portfolio

Follow Abel Hall, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abel Hall, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Abel Hall, LLC with notifications on news.